New oral drug targets Tough-to-Treat leukemia
Disease control
Terminated
This early-stage trial tests an experimental oral drug called GB3226 in adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug works by blocking two pathways that help leukemia cells grow. The study aims to find a safe dose and check f…
Phase: PHASE1 • Sponsor: Galecto Biotech AB • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC